← 홈

ADC · 고형암 (전체)

357개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 357개
ADCBiologicAstraZenecaderuxtecan plus fluoropyrim…Phase 3

FLOT Chemotherapy (FLOT Chemotherapy)

Gastrointestinal Neoplasms; Esophagogastric Junction · Gastroesophageal Adenocarcinoma

#GastroesophagealAdenocarcinoma#ADC#Phase3#인기#항체약물접합체+5
임상시험 50상태 RECRUITING
ADCBiologicMerckvedotin after avelumabPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 15.6%임상시험 50상태 RECRUITING
ADCBiologicAstellas Pharma Incvedotin after avelumabPhase 1

Enfortumab (Enfortumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 15.6%임상시험 49상태 ACTIVE
ADCBiologicStrata OncologyPhase 2

encorafenib + binimetinib (encorafenib + binimetinib)

Cancer; Advanced Solid Tumor · Cancer

#Cancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 66.7%임상시험 48상태 DISCONTINUED
ADCBiologicSWOG Cancer Research NetworkPhase 3

Cyclin-Dependent Kinase 6 Inhibitor (Cyclin-Dependent Kinase 6 Inhibitor)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 24%임상시험 47상태 RECRUITING
ADCBiologicSichuan Baili Pharmaceutical Co…viaPhase 2

BL-B01D1 (BL-B01D1)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 44상태 RECRUITING
ADCBiologicAstraZenecaDeruxtecan-Dlnk Quantificat…Approved

Dato-DXd (Datopotamab Deruxtecan, Datopotamab Deruxtecan (Dato-DXd))

Advanced Solid Malignancies · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Approved#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 79%임상시험 43상태 RECRUITING
ADCBiologicCancer Research UKvedotin, and venetoclax dem…Phase 3

Entrectinib (Entrectinib)

Haematological Malignancy; Solid Tumour · Advanced Breast Carcinoma

#AdvancedBreastCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 11.5%임상시험 42상태 DISCONTINUED
ADCBiologicExelixisPhase 2

Cabozantinib S-malate (Cabozantinib S-malate)

Differentiated Thyroid Gland Carcinoma; Follicular Variant Thyroid Gland Papillary Carcinoma · Infiltrating Bladder Urothelial Carcinom

#InfiltratingBladderUrothelialCar#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 25%임상시험 41상태 RECRUITING
ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5
효능 ORR 19%임상시험 41상태 RECRUITING
ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5
임상시험 41상태 RECRUITING
ADCBiologicMirati Therapeutics Inc.Phase 3

Sitravatinib (Sitravatinib)

Clear Cell Renal Cell Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 33.3%임상시험 35상태 DISCONTINUED
ADCBiologicBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING
ADCBiologicstaleAmgenPhase 2

Intensity-Modulated Radiotherapy (Intensity-Modulated Radiotherapy)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 38%임상시험 31상태 RECRUITING
ADCBiologicstaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Immunotherapy (Neoadjuvant and Adjuvant Immunotherapy)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 10%임상시험 31상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 31상태 RECRUITING
ADCBiologicstaleAtreca, Inc.Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 59%임상시험 31상태 RECRUITING
ADCBiologicstaleBioNTech SEPhase 2

Paroxetine (Paroxetine)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 31상태 RECRUITING
ADCBiologicstaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Enfortumab Vedotin)

Bellini Carcinoma; Collecting Duct Carcinoma · Bellini Carcinoma

#BelliniCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6%임상시험 31상태 RECRUITING
ADCBiologicstaleCastilla-La Mancha Health Servi…Phase 2

Perioperative treatment (Perioperative treatment)

Hepatoid Adenocarcinoma of Stomach · Hepatoid Adenocarcinoma of Stomach

#HepatoidAdenocarcinomaofStomach#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 31상태 RECRUITING

4 / 18 페이지

← 이전다음 →